Dr. Zamiri is a clinician-scientist who specializes in ophthalmology.
She comes to Graybug after a tenure at Novartis Pharmaceuticals, where she was vice president, global head of clinical development, and therapeutic area head for ophthalmology. At Novartis she led a group of clinical scientists and ophthalmologists.
“I am excited about Graybug’s sustained ocular delivery technologies and their potential to alleviate the treatment burden while delivering better clinical outcomes for patients with vision-threatening diseases like wet [macular degeneration],” said Dr. Zamiri.
More articles on surgery centers:
4 COVID-19 supply considerations for ASCs
5 hospitals, health systems opening or planning ASCs
ASCs reopening to patients: Check these 7 boxes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
